RxDoctor Payments Data

Lisha Porch-Petitt

Clinical Nurse Specialist · Tulsa, OKNPI 1104054147

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 30.0% of the total. 2025 is the largest year on record at $372, more than ten times the $19 reported in 2021. That places this record below the midpoint for clinical nurse specialist clinicians in OK, where the typical reported total is $852.

$456in general payments, 2019–2025

Across 23 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$137
  • Medtronic$107
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
  • Vertex$31
  • Pacira Pharmaceuticals Incorporated$24
  • Saluda Medical Americas, Inc.$21
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$456 in reported general payments places this provider in the 35th percentile of 56 clinical nurse specialist providers in Oklahoma.

See all clinical nurse specialist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$75,378
Medicare patients
301
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl124$109,316
Buprenorphine175$46,960
Buprenorphine Hcl518$20,132
ButransBuprenorphine16$7,522
Gabapentin411$6,415
Acetaminophen-CodeineAcetaminophen With Codeine183$4,673
Pregabalin299$4,585
Naloxone Hcl60$3,826
Baclofen244$3,545
Tramadol Hcl407$3,446
Tizanidine Hcl246$2,553
Lidocaine22$2,434
Diclofenac Sodium61$2,306
Naltrexone Hcl61$1,759
Tramadol Hcl ErTramadol Hcl41$1,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$137$109,316124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 56 clinical nurse specialist providers in Oklahoma.

Other clinical nurse specialist in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →